Ocular Drug Delivery Devices Market Size & Share, by Type (Topical, Iontophoresis, Ocular Insert, Intraocular Implants, In-situ Gel); Drug Form (Solution, Suspension, Emulsion, & Others); Disease Type (Glaucoma, Diabetic Macular Edema, Diabetic Retinopathy, Macular Degeneration, Cataract, Refractive Issues); End-user (Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers, Homecare Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4029
  • Published Date: Apr 20, 2023
  • Report Format: PDF, PPT

Companies Dominating the Ocular Drug Delivery Devices Landscape

top-features-companies
    • Bausch Health Companies Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis 
    • Taiwan Liposome Company, Ltd.
    • Ocular Therapeutix, Inc.
    • Kiora Pharmaceuticals, Inc.
    • Graybug Vision Inc.
    • Apellis Pharmaceuticals, Inc.
    • Implanet Company
    • Aerie Pharmaceuticals Inc.
    • EyePoint Pharmaceuticals, Inc.
    • Protalix BioTherapeutics

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • EyePoint Pharmaceuticals, Inc. announced the interim data from its ongoing Phase 1 DAVIO trial of EYP-1901 for the potential treatment of wet AMD.

  • EyeGate Pharmaceuticals, Inc. announced the first successful dosage of its drug PP-001 in the phase II proof-of-concept (“POC”) study of ocular surface inflammation. PP-001 is an inhibitor of dihydroorotate dehydrogenase


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4029
  • Published Date: Apr 20, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing prevalence of ocular diseases and growing awareness amongst people regarding vision impairment are estimated to boost the market growth

The market is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023-2035.

High competition from generic products and discomfort such as irritation and excessive lachrymation is estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Bausch Health Companies Inc., Taiwan Liposome Company, Ltd., Ocular Therapeutix, Inc., Kiora Pharmaceuticals, Inc., Graybug Vision Inc., Apellis Pharmaceuticals, Inc., Implanet Company, and Aerie Pharmaceuticals Inc. EyePoint Pharmaceuticals, Inc., Protalix BioTherapeutics.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, drug type, disease type, end-user, and by region.

The ophthalmic clinics segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying